Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Podcasts

Treatment Shows Disease-free Survival Benefit in Patients With NSCLC

Julie Gould
Maria Asimopoulos

 

Headshot of Nasser Altorki, MD, on a blue background underneath the PopHealth Perspectives logo.Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to best supportive care in patients with non-small cell lung cancer that had already received first line chemotherapy.

 

 

Advertisement

Advertisement

Advertisement